To address uncertainties in statin safety profiles, which are often based on observational data susceptible to bias, researchers conducted a definitive meta-analysis of individual participant data from major double-blind, randomized controlled trials. The study first identified all undesirable effects listed in the official Summaries of Product Characteristics (SmPCs) for five common statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin). The analysis then focused exclusively on high-quality evidence from trials with over 1000 participants, a minimum 2-year treatment period, and a double-blind design comparing either statin versus placebo or more intensive versus less intensive statin regimens. The core analysis pooled data from 19 placebo-controlled trials involving 123,940 participants (median follow-up 4.5 years), calculating event rate ratios (RRs) with a stringent 5% false discovery rate (FDR) control to minimize false-positive findings. The results were striking: beyond the well-established risks for muscle symptoms and increased diabetes incidence, only 4 out of 66 other listed undesirable outcomes showed a statistically significant association with statin therapy. These were: abnormal liver transaminases (RR 1.41), other liver function test abnormalities (RR 1.26; combined absolute annual excess risk of 0.13%), urinary composition alteration (RR 1.18), and oedema (RR 1.07). A secondary analysis of 4 trials comparing intensive vs. standard statin dosing confirmed a dose-dependent effect for liver abnormalities, but found no significant excess for urinary changes or oedema, suggesting those effects may not be dose-related. Critically, this robust methodology did not confirm statistical links for many symptoms commonly attributed to statins in non-blinded settings, such as numerous neuropsychiatric, gastrointestinal, dermatological, and other complaints. The findings provide high-level evidence that the proven cardiovascular benefits of statin therapy are accompanied by a very short list of confirmed, generally low-incidence side effects, offering clarity for both clinicians and patients regarding true risk profiles. Source: https://www.thelancet.com/
